Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14137239 | 0.91 | MAPT (0.49) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2919596 | 0.90 | MAPT (0.48) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2915461 | 0.90 | SIRT2 (0.45) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13175613 | 0.89 | MAPT (0.48) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2915403 | 0.88 | PTGES (0.47) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13175801 | 0.87 | S1PR4 (0.44) | MAPTALDH1A1MEN1KMT2APDGFRA | |
| SCHEMBL13956879 | 0.85 | MAPT (0.48) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13175990 | 0.83 | ALDH1A1 (0.52) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2919415 | 0.82 | ALDH1A1 (0.51) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2919440 | 0.82 | ALDH1A1 (0.51) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | claimed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | claimed |
| JP-2007517887-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1709047-A2 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-10-11 | — | — | EP | claimed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | claimed |
| WO-2005067900-A2 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1709047-B1 | AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439374-B2 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | MAPT 4038/4885NPC1 886/4885RAB9A 3144/4885 |
| US-20050228013-A1 | Azabenzofuran substituted thioureas; inhibitors of viral replication | NAT1, PIGS, ADORA1 | MAPT 4359/4885NPC1 491/4885RAB9A 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.